Repeat PET/CT Imaging of Patients With Amyloid 124I-AT-01 to Measure Changes in Organ-specific Amyloid Load

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

December 7, 2022

Primary Completion Date

August 1, 2023

Study Completion Date

September 1, 2023

Conditions
Systemic Amyloidosis
Interventions
DRUG

Injection of peptide p5+14 radiolabeled with iodine-124 (124I-AT-01)

124I-AT-01 (124I-p5+14, iodine-124I evuzamitide) is a a novel iodine-124 (124I) labeled 45 L-amino acid peptide suitable for PET/CT imaging that has been shown to bind systemic amyloid deposits of diverse types in all organs, including the heart. The peptide binds amyloid through multivalent electrostatic interactions with the amyloid fibril and ubiquitous heparan sulfate proteoglycans.

Trial Locations (1)

37920

University of Tennessee Graduate School of Medicine, Knoxville

All Listed Sponsors
lead

University of Tennessee Graduate School of Medicine

OTHER